| Total (n = 234) | Non survivors (n = 52) | Survivors (n = 182) | Pvalue |
---|---|---|---|---|
Age, median years (range) | 57 (19 ~ 93) | 60.5 (19 ~ 84) | 56 (21 ~ 93) | 0.35 |
Male sex | 92 (39.3%) | 23 (44.2%) | 69 (37.9%) | 0.41 |
Underlying disease | ||||
 Diabetes mellitus | 47 (20.1%) | 8 (15.4%) | 39 (21.4%) | 0.34 |
 Hypertension | 52 (22.2%) | 11 (21.2%) | 41 (22.5%) | 0.83 |
 Liver cirrhosis | 13 (5.6%) | 2 (3.8%) | 11 (6.0%) | 0.54 |
 Transplant | 34 (14.5%) | 10 (19.2%) | 24 (13.2%) | 0.27 |
 Solid organ | 8 (3.4%) | 1 (1.9%) | 7 (3.8%) |  |
 Bone marrow | 26 (11.1%) | 9 (17.3%) | 17 (9.3%) |  |
 Malignancy | 68 (29.1%) | 14 (26.9%) | 54 (29.7%) | 0.70 |
 Dialysis | 11 (4.7%) | 2 (3.8%) | 9 (4.9%) | 0.74 |
Neutropenia | 54 (23.1%) | 18 (34.6%) | 36 (19.8%) | 0.02 |
Hospitalization in the preceding 90Â days | 98 (41.9%) | 26 (50.0%) | 72 (39.6%) | 0.18 |
APACHE II score, median (IQR) | 12 (0 ~ 40) | 18 (5 ~ 40) | 11 (0 ~ 28) | 0.0001 |
Charlson comobidity index, median (IQR) | 3 (0 ~ 13) | 4 (1 ~ 10) | 4 (0 ~ 13) | 0.57 |
Septic shock | 62 (26.7%) | 28 (53.8%) | 34 (18.7%) | 0.0001 |
Invasive procedure | ||||
 Central venous catheter | 97 (41.5%) | 36 (69.2%) | 61 (33.5%) | 0.0001 |
 Surgical drainage | 39 (16.7%) | 8 (15.4%) | 31 (17.0%) | 0.78 |
 Foley catheter | 50 (21.4%) | 28 (53.8%) | 22 (12.1%) | 0.0001 |
 Mechanical ventilator | 32 (13.7%) | 20 (38.5%) | 12 (6.6%) | 0.0001 |
The length of stay before bacteremia, median days (IQR) | 1 (0 ~ 92) | 1 (0 ~ 28) | 2.5 (0 ~ 92) | 0.2 |
Source of bacteremia | Â | Â | Â | 0.006 |
 Pneumonia | 70 (29.9%) | 27 (51.9%) | 43 (23.6%) |  |
 Urinary tract | 18 (7.7%) | 2 (3.8%) | 16 (8.8%) |  |
 Vascular catheter-related | 4 (1.7%) | 1 (1.9%) | 3 (1.6%) |  |
 Intra-abdomen | 42 (17.9%) | 7 (13.5%) | 35 (19.2%) |  |
 Postoperative wound | 11 (4.7%) | 1 (1.9%) | 10 (5.5%) |  |
 Unknown | 89 (38.0%) | 14 (26.9%) | 75 (41.2%) |  |
Length of hospital stay, median days (IQR) | 17 (1 ~ 364) | 12 (1 ~ 364) | 18 (1 ~ 92) | 0.08 |
Carbapenem resistance | 118 (50.4%) | 26 (50.0%) | 92 (50.5%) | 0.94 |
Multidrug resistance | 6 (2.6%) | 3 (5.8%) | 3 (1.6%) | 0.09 |